2024-07-13 10:00:00 ET
Summary
- CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia.
- However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper their near-term expectations.
- At the same time, CRSP does not own the patent of its gene editing technology, with a patent battle still occurring between the two groups of inventors.
- As the stock continues to trade sideways since November 2021, we believe that its intermediate-term investment thesis is likely tied to its swing trade potential.
- CRSP is likely to remain volatile as well, attributed to the elevated short interest and intense insider selling, with it only suitable for investors with higher risk tolerance.
CRSP's Gene Editing Technology Has Finally Been Approved
CRSP's Gene Editing Technology
CRISPR Therapeutics AG ( CRSP ) is a biotech company specializing in genetic editing technology, namely the Clustered Regularly Interspaced Short Palindromic Repeats [CRISPR]-associated protein 9, CRISPR-Cas9, allowing the precise alteration of specific sequences of genomic DNA ....
Read the full article on Seeking Alpha
For further details see:
Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle